{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T02:26:28Z","timestamp":1781317588146,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ando.2020.12.007","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T10:21:01Z","timestamp":1607854861000},"page":"187-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Managing carcinoid heart disease in patients with neuroendocrine tumors"],"prefix":"10.1016","volume":"82","author":[{"given":"Apostolos","family":"Koffas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Toumpanakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2020.12.007_bib0250","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"69","author":"Davar","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ando.2020.12.007_bib0255","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCIMAGING.109.886846","article-title":"Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI","volume":"3","author":"Bhattacharyya","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ando.2020.12.007_bib0260","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11936-013-0265-2","article-title":"Carcinoid valve disease","volume":"15","author":"Askew","year":"2013","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.ando.2020.12.007_bib0265","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ahj.2014.03.018","article-title":"Carcinoid heart disease: current understanding and future directions","volume":"167","author":"Patel","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.ando.2020.12.007_bib0270","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000335629","article-title":"Barcelona Consensus Conference Participants. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas","volume":"95","author":"Pape","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ando.2020.12.007_bib0275","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum","volume":"103","author":"Niederle","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ando.2020.12.007_bib0280","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ando.2020.12.007_bib0285","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Relationship of circulating vasoactive substances to ultrasound detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.ando.2020.12.007_bib0290","doi-asserted-by":"crossref","first-page":"378e81","DOI":"10.1016\/j.amjcard.2007.08.045","article-title":"Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century","volume":"101","author":"Bhattacharyya","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ando.2020.12.007_bib0295","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1161\/CIRCULATIONAHA.105.553750","article-title":"Prognosis of carcinoid heart disease: analysis of 200 cases over two decades","volume":"112","author":"M\u00f8ller","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ando.2020.12.007_bib0300","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid heart disease: from pathophysiology to treatment\u00a0\u2013\u00a0\u2018Something in the way it moves\u2019","volume":"101","author":"Grozinsky-Glasberg","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ando.2020.12.007_bib0305","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/CIRCULATIONAHA.107.701367","article-title":"Carcinoid heart disease","volume":"116","author":"Bhattacharyya","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ando.2020.12.007_bib0310","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2008.18.7047","article-title":"Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor","volume":"27","author":"Korse","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2020.12.007_bib0315","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/curroncol13020006","article-title":"Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group","volume":"13","author":"Maroun","year":"2006","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ando.2020.12.007_bib0320","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/cncr.11226","article-title":"Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor","volume":"97","author":"Zuetenhorst","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2020.12.007_bib0325","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0735-1097(98)00354-4","article-title":"Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease","volume":"32","author":"Denney","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ando.2020.12.007_bib0330","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjcard.2010.12.025","article-title":"Risk factors for the development and progression of carcinoid heart disease","volume":"107","author":"Bhattacharyya","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ando.2020.12.007_bib0335","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.amjcard.2008.05.047","article-title":"Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease","volume":"102","author":"Bhattacharyya","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ando.2020.12.007_bib0340","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/sj.bjc.6601816","article-title":"Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease","volume":"90","author":"Zuetenhorst","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ando.2020.12.007_bib0345","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021451","article-title":"Factors associated with progression of carcinoid heart disease","volume":"348","author":"M\u00f8ller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.12.007_bib0350","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1046\/j.0007-1323.2001.01798.x","article-title":"Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome","volume":"88","author":"Westberg","year":"2001","journal-title":"Br J Surg"},{"key":"10.1016\/j.ando.2020.12.007_bib0355","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.amjcard.2010.01.017","article-title":"Echocardiographic follow-up of treated patients with carcinoid syndrome","volume":"105","author":"Mansencal","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ando.2020.12.007_bib0360","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000360767","article-title":"Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease","volume":"99","author":"Dobson","year":"2014","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ando.2020.12.007_bib0365","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcct.2010.08.009","article-title":"Computed tomography of cardiac and pericardiac masses","volume":"5","author":"Rajiah","year":"2011","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.ando.2020.12.007_bib0370","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijcard.2008.10.031","article-title":"Accuracy and reproducibility of assessing right ventricular function with 64-section multi-detector row CT: comparison with magnetic resonance imaging","volume":"139","author":"Guo","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ando.2020.12.007_bib0375","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pcad.2006.12.002","article-title":"Carcinoid heart disease","volume":"49","author":"Bernheim","year":"2007","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ando.2020.12.007_bib0380","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2020.12.007_bib0385","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.12.007_bib0390","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ando.2020.12.007_bib0395","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.ando.2020.12.007_bib0400","first-page":"81","article-title":"Above-label doses of octreotide LAR in patients with metastatic small intestinal carcinoid tumors","volume":"6","author":"Strosberg","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.ando.2020.12.007_bib0405","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90-Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2020.12.007_bib0410","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2020.12.007_bib0415","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2020.12.007_bib0420","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ando.2020.12.007_bib0425","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2020.12.007_bib0430","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2014-2247","article-title":"Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial","volume":"100","author":"Pavel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.007_bib0435","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2020.12.007_bib0440","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2020.12.007_bib0445","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12672-015-0233-2","article-title":"Symptomatic control of neuroendocrine tumours with everolimus","volume":"6","author":"Bainbridge","year":"2015","journal-title":"Horm Cancer"},{"key":"10.1016\/j.ando.2020.12.007_bib0450","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0033-1333651","article-title":"Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases","volume":"30","author":"Gupta","year":"2013","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.ando.2020.12.007_bib0455","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.beem.2007.01.005","article-title":"Cytotoxic treatment including embolization\/chemoembolization for neuroendocrine tumours","volume":"21","author":"Toumpanakis","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2020.12.007_bib0460","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0025-6196(11)60834-3","article-title":"Role of hepatic resection for patients with carcinoid heart disease","volume":"83","author":"Bernheim","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ando.2020.12.007_bib0465","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jacc.2015.09.014","article-title":"Early and late outcomes of surgical treatment in carcinoid heart disease","volume":"66","author":"Connolly","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ando.2020.12.007_bib0470","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejcts.2010.10.035","article-title":"Outcomes, risks and complications of cardiac surgery for carcinoid heart disease","volume":"40","author":"Bhattacharyya","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ando.2020.12.007_bib0475","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.hlc.2019.05.183","article-title":"Early outcomes of surgery for carcinoid heart disease","volume":"29","author":"Yong","year":"2020","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.ando.2020.12.007_bib0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2018.09.025","article-title":"Improving outcome of valve replacement for carcinoid heart disease","volume":"158","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ando.2020.12.007_bib0485","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/fca.10.87","article-title":"Surgery for carcinoid heart disease: current outcomes, concerns and controversies","volume":"6","author":"Raja","year":"2010","journal-title":"Future Cardiol"},{"key":"10.1016\/j.ando.2020.12.007_bib0490","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000437167","article-title":"Staged catheter-based valve treatment of severe carcinoid heart disease","volume":"103","author":"Laule","year":"2016","journal-title":"Neuroendocrinology"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620313172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426620313172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:53:39Z","timestamp":1757717619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426620313172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":49,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0003426620313172"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2020.12.007","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing carcinoid heart disease in patients with neuroendocrine tumors","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}